In a study, Abbott's Perclose had 9.3% access-site complications; LockeT had 1.2%.
Catheter Precision, a subsidiary of Flyte Aviation (VJET), published a study in The Journal of Interventional Cardiology comparing its LockeT device to Abbott's Perclose. LockeT showed fewer complications (1.2% vs. 9.3%) and zero device failures, while both had similar hemostasis times. LockeT is FDA-registered and CE Mark-approved, sold in the US, Europe, and South America.
How this was made
The 30-second read
Why it matters
The study provides fresh safety data that could shift clinician preference and affect sales expectations for both Abbott and Flyte Aviation's medical subsidiary.
Market read
First disclosure of comparative clinical data may influence device adoption and affect stock sentiment for Abbott (ABT) and Flyte Aviation (VJET).
What to watch
Regulatory approvals, reimbursement policies, and adoption rates will ultimately determine market impact.
Background
The press release announces the first peer‑reviewed comparative study of a new suture retention device (LockeT) versus Abbott's established Perclose VCD, highlighting lower complication rates for LockeT.
Ticker impact
Abbott's Perclose device showed 9.3% access-site complications versus 1.2% for the competing LockeT device in a newly published study.
likely downside as clinicians may prefer the lower-complication LockeT device.
The study is the first public disclosure of comparative safety data, which could affect market perception of Abbott's vascular closure product line.
Flyte Aviation's subsidiary Catheter Precision released the study showing its LockeT device outperforms Abbott's Perclose.
potential upside as the study may drive demand for LockeT and raise visibility for Flyte Aviation's medical segment.
First disclosure of favorable trial results for the LockeT device could boost investor sentiment toward the parent company.
Market effects
May influence the broader vascular closure device market and encourage competition.
U.S. and European medical device markets could see increased interest in suture retention technologies.
Limited to medical device sector; no broad macro impact.
Counterpoint
Investors may view the study as a niche finding with limited commercial impact on Abbott's overall portfolio.
Key entities
- CompanyAbbott Laboratories
Manufacturer of the Perclose vascular closure device.
- CompanyFlyte Aviation, Inc.
Parent company of Catheter Precision, which developed the LockeT device.
- CompanyCatheter Precision
Subsidiary of Flyte Aviation that created the LockeT suture retention device.




